These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 12433354

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside.
    Cuenca-Estrella M.
    Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():54-9. PubMed ID: 24372680
    [Abstract] [Full Text] [Related]

  • 4. [Antifungals cellular targets and mechanisms of resistance].
    Accoceberry I, Noël T.
    Therapie; 2006 Jun; 61(3):195-9. PubMed ID: 16989119
    [Abstract] [Full Text] [Related]

  • 5. [New systemic antifungal drugs: mechanisms of action, drug interactions and side effects].
    Schäfer-Korting M.
    Mycoses; 2003 Jun; 46 Suppl 1():28-31. PubMed ID: 12955850
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH.
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [Abstract] [Full Text] [Related]

  • 9. In vitro evaluation of combination of terbinafine with itraconazole or amphotericin B against Zygomycota.
    Gómez-López A, Cuenca-Estrella M, Mellado E, Rodríguez-Tudela JL.
    Diagn Microbiol Infect Dis; 2003 Mar; 45(3):199-202. PubMed ID: 12663161
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Antifungal agents in the treatment of systemic infections: Relevance of mechanism of action, activity profile and resistances].
    Cuenca-Estrella M.
    Rev Esp Quimioter; 2010 Dec; 23(4):169-76. PubMed ID: 21191554
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.
    Gilgado F, Serena C, Cano J, Gené J, Guarro J.
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4211-3. PubMed ID: 17015631
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [The latest diagnosis and treatment on deep-seated mycosis. Expectations for micafungin, the first candin in Japan (discussion)].
    Kohno S, Niki Y, Takematsu Y, Yoshida M.
    Jpn J Antibiot; 2003 Feb; 56(1):1-14. PubMed ID: 12723394
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.